1.Rapid determination of tramadol in urine by surface-enhanced Raman spectroscopy
Xiaojing YAO ; Peiying JI ; Feng LU ; Guorong SHI ; Xiang FU
Journal of Pharmaceutical Practice and Service 2025;43(4):185-189
Objective To establish a method for rapid detection of tramadol in urine by liquid-liquid extraction(LLE)-surface-enhanced Raman spectroscopy (SERS). Methods Tramadol was extracted from urine with chloroform∶isopropyl alcohol (9∶1) extractant and detected in urine samples by enhanced Raman spectroscopy (wavelength 785 nm). Results The quantitative curve of tramadol was Y=204.35 X−465.62, r=
2.Clinical efficacy analysis of Shibao Decoction in the treatment of late-onset hypogonadism with kidney essence deficiency.
Shao-Kang CHEN ; Yi SHAN ; Zhen-Fu SHI ; Hai-Feng XU ; Yao-Hua ZHANG ; Yi LU
National Journal of Andrology 2025;31(7):630-636
OBJECTIVE:
To evaluate the clinical efficacy of "Shibao Decoction" in the management of late-onset hypogonadism (LOH) caused by deficiency of kidney essence.
METHODS:
Sixty male patients with late-onset hypogonadism of kidney essence deficiency type were randomly assigned to the treatment group and the control group, each with 30 cases. The patients in treatment group were treated with oral Shibao Decoction, while the control group was treated with oral Testosterone Undecanoate Capsules. The patients in both groups were treated for 12 weeks. The PADAM symptom score, TCM syndrome score, serum total testosterone (TT), serum free testosterone (FT), sex hormone binding globulin (SHBG), body mass index (BMI), total skeletal muscle mass index (SMI), appendicular skeletal muscle mass index (ASMI), FBG, FINS, and insulin resistance index (HOMA-IR) levels were compared between the two groups.
RESULTS:
After treatment, PADAM scores for each item and TCM symptoms score decreased, TT and FT increased in both groups, all with statistically significant differences from those of pre-treatment (P<0.05). The level of SHBG in the control group decreased (P<0.05), which had not changed significantly in the treatment group (P>0.05). After treatment, SMI and ASMI increased in both groups significantly (P<0.05). BMI decreased in the control group (P<0.05), which had not changed significantly in the treatment group (P>0.05). The level of FINS decreased in the control group (P<0.05), which had not changed significantly in the treatment group (P>0.05). FPG had not changed significantly in both groups (P>0.05), and the insulin resistance index (HOMA-IR) had significantly improved in both groups, all with statistically significant differences from those of pre-treatment (P<0.05). After treatment, the total effective rates of PADAM score and TCM syndrome score in the treatment group were 73.3% and 86.6% respectively, and the total effective rates in the control group were 66.7% and 76.6% respectively. The total effective rates of the two scores in the treatment group were slightly higher than those in the control group (P>0.05). There was no significant difference in the indicators between the two groups after treatment, and the treatment group is generally comparable with the control group in the therapeutic effects (P>0.05). And no adverse reactions occurred during treatment in both groups.
CONCLUSION
The "Shibao Decoction" has a remarkable therapeutic effect on late-onset hypogonadism caused by deficiency of kidney essence and has good safety. It can be used as an alternative to testosterone undecanoate and is worthy of clinical promotion and application.
Humans
;
Hypogonadism/etiology*
;
Drugs, Chinese Herbal/therapeutic use*
;
Male
;
Testosterone/therapeutic use*
;
Treatment Outcome
;
Sex Hormone-Binding Globulin
;
Medicine, Chinese Traditional
;
Middle Aged
;
Adult
;
Kidney
3.Comparison of the clinical efficacy and safety of DC-CIK loaded with different antigens in the treatment of malignant melanoma
HE Yuan1 ; ZHOU Xiaoxian1 ; ZHANG Yan1 ; SHI Ruifang1 ; WANG Jing1 ; WANG Zixuan1 ; WANG Zhongda1 ; ZHU Yue1 ; SHU Yan1 ; WANG Jing1 ; YAO Lu1 ; FU Gongbo1 ; LEI Zengjie1 ; JIA Shaochang1 ; JIANG Longwei1,2
Chinese Journal of Cancer Biotherapy 2025;32(12):1280-1284
[摘 要] 目的:回顾性分析树突状细胞-细胞因子诱导的杀伤细胞(DC-CIK)不同抗原负载后在治疗恶性黑色素瘤(MM)中的临床疗效与安全性。方法:采集2012年10月至2024年12月期间东部战区总医院秦淮医疗区收治的42例晚期MM患者的外周血单个核细胞,经实验室体外诱导培养成DC和CIK。根据患者HLA-A2的表达将患者分为多肽组和细胞组,多肽组负载混合多肽,细胞组负载肿瘤细胞A375裂解物。DC与CIK培养成熟后再回输给患者。比较两组患者的客观临床反应及生存期,检测治疗前后两组患者外周血淋巴细胞亚群,观察患者回输后的不良反应。结果:42例MM患者中,0例达CR,0例PR,31例SD,11例PD;其中,多肽组18例SD,6例PD,细胞组13例SD,5例PD。多肽组疾病控制率为75.0%,细胞组为72.2%;42例患者中死亡12例,其中细胞组4例,多肽组8例。1年OS率多肽组为76.6%,细胞组为66.7%;2年OS率多肽组为43.8%,细胞组为66.7%;3年OS率多肽组为43.8%,细胞组为33.3%,多肽组3年OS率略高于细胞组,但两组之间无统计学差异(P = 0.445)。两组MM患者治疗前后淋巴细胞亚群无显著差异(均P > 0.05),两组患者均未出现严重不良反应。结论:细胞负载DC-CIK与混合多肽负载DC-CIK治疗MM患者是安全的,能使患者临床获益,但两组的近期疗效和长期生存有差异以及免疫反应均无显著性差异。
4.The effects and possible mechanisms of SRSF7 on the proliferation, migration, and invasion of HepG2 cells
SHI Weiye ; YAO Xu ; FU Yu ; CAO Yirao ; WANG Yingze
Chinese Journal of Cancer Biotherapy 2024;31(9):864-870
[摘 要] 目的:探讨富含丝氨酸/精氨酸剪接因子7(SRSF7)对肝细胞癌(HCC)细胞HepG2增殖、迁移和侵袭的影响及其可能机制。方法:通过癌症基因组图谱(TCGA)和Kaplan-Meier Plotter在线分析SRSF7在HCC和癌旁组织中的差异表达及其与患者预后的关系。常规培养HepG2细胞,用转染试剂将SRSF7 RNA敲减序列(siSRSF7#1和siSRSF7#2)、对照序列(NC)、SRSF7过表达载体(hSRSF7-oe)和对照载体(hSRSF7-nc)转染至HepG2细胞中,实验分为NC组、siSRSF7#1组、siSRSF7#2组、NC + hSRSF7-nc组、siSRSF7 + hSRSF7-nc组和siSRSF7 + hSRSF7-oe组。通过qPCR和WB法检测各组HepG2细胞中SRSF7 mRNA和蛋白的表达,MTS实验、平板克隆形成实验、划痕愈合实验、Transwell小室实验分别检测各组HepG2细胞的增殖、迁移和侵袭的能力。WB法检测各组HepG2细胞中JAK1/STAT3信号通路的相关蛋白的表达。结果:数据库数据分析显示SRSF7 mRNA在HCC组织中呈高表达(P < 0.001),SRSF7 mRNA高表达与HCC患者不良预后有关联(P < 0.05)。敲减SRSF7后,HepG2细胞的增殖、迁移和侵袭能力均显著下降(均P < 0.01)。敲减SRSF7组细胞中JAK1和STAT3磷酸化水平显著降低(均P < 0.05),同时过表达SRSF7后,JAK1和STAT3磷酸化水平又明显升高(均P < 0.05)。结论:SRSF7在HCC组织中呈高表达,其可能通过调控JAK1/STAT3信号通路促进HepG2细胞的增殖、迁移和侵袭。
5.Downregulation of SRSF6 Inhibits the Macrophage Inflammatory Response by Regulating the Alternative Splicing of MyD88
Yu FU ; Lu-Yao ZHANG ; Bo CHENG ; Wei-Ye SHI ; Ni LI ; Ying-Ze WANG
Chinese Journal of Biochemistry and Molecular Biology 2024;40(11):1563-1573
Serine/arginine-rich splicing factor 6 (SRSF6) is a member of the serine and arginine-rich (SR) protein family,and it plays a crucial regulatory role in RNA splicing.Dysregulation of SRSF6 ex-pression or function can lead to aberrant alternative splicing of certain genes,and contribute to the devel-opment and progression of inflammatory diseases,including tumors,diabetes,and pleural fibrosis.How-ever,the role of SRSF6 in inflammation remains unclear.In this study,we found that the expression of inflammatory factors,including tumor necrosis factor-α(TNF-α) and cyclooxygenase-2 (COX-2),was induced by lipopolysaccharides (LPS) .Concurrently,both the levels of SRSF6 mRNA and protein ex-pression significantly increased with prolonged LPS stimulation (P<0.05) .Furthermore,we investigated the change of SRSF6 expression on the expression of inflammatory factors.The results showed that upreg-ulation of SRSF6 enhanced the expression of LPS-induced inflammatory factors (P<0.05),while down-regulation of SRSF6 inhibited their expression (P<0.05) .Additionally,the activation of the nuclear fac-tor-κB (NF-κB) and mitogen-activated protein kinase (MAPK) signaling pathways was suppressed by SRSF6 knockdown (P<0.05),indicating that SRSF6 is involved in regulating inflammatory responses in macrophages.Myeloid differentiation factor 88 (MyD88) is a key adaptor protein in the TLR4 signaling pathway,with its splicing isoforms MyD88-L and MyD88-S exerting pro-inflammatory and anti-inflamma-tory effects,respectively.Analysis of RNA-binding protein database and RNA immunoprecipitation showed that SRSF6 binds to MyD88 mRNA.Splicing analysis indicated that downregulation of SRSF6 promoted the expression of the anti-inflammatory MyD88-S mRNA isoform (P<0.01) .Moreover,knock-down of MyD88-S could rescue the expression of inflammatory factors suppressed by SRSF6 downregula-tion.These findings suggest that SRSF6 regulates MyD88 alternative splicing in macrophages,thereby af-fecting the activation of inflammatory signaling pathways and the expression of inflammatory factors.This study provides a foundation for further elucidating the role of SRSF6 in inflammatory diseases.
6.Propionic and butyric acid levels can predict ability in the activities of daily living after an ischemic stroke
Hankui YIN ; Zhongli WANG ; Ming ZENG ; Ming SHI ; Yun REN ; Linhua TAO ; Yunhai YAO ; Jianming FU ; Xudong GU
Chinese Journal of Physical Medicine and Rehabilitation 2024;46(7):631-634
Objective:To seek a correlation between short-chain fatty acids (SCFAs) and skill in the activities of daily living (ADL) after an ischemic stroke.Methods:Ninety ischemic stroke survivors were assessed using the Barthel Index (BI). Fecal samples were collected and analyzed for the concentration of acetic acid, propionic acid, butyric acid, isobutyric acid, valeric acid, and isovaleric acid using gas chromatography. Spearman correlation analysis was conducted to identify SCFAs that correlated with the total BI score. Linear regressions were evaluated to explore the correlation between the total BI score and SCFAs.Results:The concentrations of propionic and butyric acids in the feces were found to correlate significantly with the total BI scores. Data including propionic acid and butyric acid levels, age, gender, body mass index, disease duration, any history of hypertension or diabetes, and other SCFAs were included in the regression models. Propionic and butyric acid levels were found to be potentially useful predictors of total BI scores.Conclusions:The concentration of propionic and butyric acids in the feces after an ischemic stroke can predict the survivor′s total BI score. Those concentrations could therefore be useful for predicting ADL ability.
7.Combination of anti-inflammatory therapy and RNA interference by light-inducible hybrid nanomedicine for osteoarthritis treatment.
Li QIAO ; Zhiyao LI ; Bowen LI ; Fu ZHANG ; Zhuo YAO ; Chongzhi WU ; Honglin TANG ; Qi PAN ; Peihua SHI ; Yuan PING
Acta Pharmaceutica Sinica B 2024;14(11):5008-5025
Osteoarthritis (OA) is a type of highly prevalent heterogeneous degenerative disease that leads to joint pain, deformity, the destruction of articular cartilage, and eventual disability. The current treatment strategies for OA often suffer from systemic side effects, poor anti-inflammatory efficacy, and persistent pain. To address these issues, we develop light-inducible nanomedicine that enables the co-delivery of anti-inflammatory drug (diacerein, DIA) and small interfering RNA (siRNA) targeting nerve growth factor (NGF) for pain relief to enhance the therapeutic efficacy of OA. The nanomedicine is based on poly(β-amino-ester)-coated gold nanocages (AuNCs), which is further incorporated with the phase-change material (lauric acid/stearic acid, LA/SA). Following intra-articular (IA) injection in vivo, the nanomedicine displays high degree of drug accumulation and retention in the joint lesion of OA mouse models. The photothermal effect, induced by AuNCs, not only promotes DIA and siRNA release, but also upregulates the expression of heat shock protein 70 (HSP-70) to resist the apoptosis of chondrocytes in the inflammatory condition. The internalization of both DIA and siRNA results in strong anti-inflammatory and pain-relieving effects, which greatly contribute to the joint repair of OA mice. This study offers a promising combination strategy for OA treatment.
8.Clinical efficacy of wearing base curve aspheric orthokeratology lens in the control of myopia
Rui WANG ; Jiang LIN ; Li LI ; Si-Lin BIAN ; Xue-Mei FU ; Xin-Yao MAO ; Shi-Ping ZHOU ; Qiong WANG
International Eye Science 2023;23(4):563-566
AIM: To evaluate the clinical efficacy of wearing base curve aspheric orthokeratology(OK)lens in the control of myopia.METHODS: A prospective study was conducted. A total of 94 cases(94 eyes)of myopia aged 8~13 years old who were fitted with orthokeratology(OK)lens in our hospital from January 2020 to July 2021 were selected(for patients who received OK lens in one eye, the eye is selected as the observation eye, and for patients who receive OK lens in both eyes, the right eye is used as the observation eye). Patients were divided into two groups according to the design of the OK lens, with 46 cases wearing base curve aspheric OK lens in study group and 48 cases wearing base curve spheric OK lens in control group. The study group and the control group were further divided into low myopia group(-3.00D< SE ≤-0.75D)and moderate myopia group(-6.00D< SE ≤-3.00D)according to the baseline spherical equivalent(SE), with 52 cases(52 eyes)in the low myopia group and 42 cases(42 eyes)in the moderate myopia group. Uncorrected visual acuity(UCVA)was evaluated at 1d, 1wk, 1, 3, 6 and 9mo after wearing lenses, and axial length were measured at 6mo and 1a after wearing lenses respectively.RESULTS: All patients completed follow-up, and there was no significant differences in UCVA(LogMAR)between the study group(-0.12±0.08)and the control group(-0.17±0.07)after wearing the OK lens for 1mo(P>0.05); the mean axial length elongation between the two groups had no significant differences after wearing lenses for 6mo and 1a(all P>0.05). In the low myopia group, the axial length elongation of the study group was 0.19±0.17mm after wearing OK lens for 1a, which was significantly lower than that of the control group(0.31±0.18mm; P<0.05); while in the moderate myopia group, the axial length elongation was 0.22±0.18mm, and it had no significant differences with that in the control group(0.19±0.12mm; P>0.05). There was no significant differences in axial length elongation between the low myopia group and the moderate myopia group in study group after wearing lenses for 6mo and 1a(P>0.05), while there was differences in axial length elongation between low myopia group and moderate myopia group in the control group after wearing lenses for 6mo(0.15±0.13 vs. 0.05±0.12mm)and 1a(0.31±0.18 vs. 0.19±0.12mm; all P<0.05).CONCLUSION: Wearing base curve aspheric OK lens can effectively improve the UCVA and control the elongation of axial length. For patients with low myopia, base curve aspheric OK lens had a better efficacy in controlling the elongation of axial length than the spheric OK lens.
9.Efficacy and safety of LY01005 versus goserelin implant in Chinese patients with prostate cancer: A multicenter, randomized, open-label, phase III, non-inferiority trial.
Chengyuan GU ; Zengjun WANG ; Tianxin LIN ; Zhiyu LIU ; Weiqing HAN ; Xuhui ZHANG ; Chao LIANG ; Hao LIU ; Yang YU ; Zhenzhou XU ; Shuang LIU ; Jingen WANG ; Linghua JIA ; Xin YAO ; Wenfeng LIAO ; Cheng FU ; Zhaohui TAN ; Guohua HE ; Guoxi ZHU ; Rui FAN ; Wenzeng YANG ; Xin CHEN ; Zhizhong LIU ; Liqiang ZHONG ; Benkang SHI ; Degang DING ; Shubo CHEN ; Junli WEI ; Xudong YAO ; Ming CHEN ; Zhanpeng LU ; Qun XIE ; Zhiquan HU ; Yinhuai WANG ; Hongqian GUO ; Tiwu FAN ; Zhaozhao LIANG ; Peng CHEN ; Wei WANG ; Tao XU ; Chunsheng LI ; Jinchun XING ; Hong LIAO ; Dalin HE ; Zhibin WU ; Jiandi YU ; Zhongwen FENG ; Mengxiang YANG ; Qifeng DOU ; Quan ZENG ; Yuanwei LI ; Xin GOU ; Guangchen ZHOU ; Xiaofeng WANG ; Rujian ZHU ; Zhonghua ZHANG ; Bo ZHANG ; Wanlong TAN ; Xueling QU ; Hongliang SUN ; Tianyi GAN ; Dingwei YE
Chinese Medical Journal 2023;136(10):1207-1215
BACKGROUND:
LY01005 (Goserelin acetate sustained-release microsphere injection) is a modified gonadotropin-releasing hormone (GnRH) agonist injected monthly. This phase III trial study aimed to evaluated the efficacy and safety of LY01005 in Chinese patients with prostate cancer.
METHODS:
We conducted a randomized controlled, open-label, non-inferiority trial across 49 sites in China. This study included 290 patients with prostate cancer who received either LY01005 or goserelin implants every 28 days for three injections. The primary efficacy endpoints were the percentage of patients with testosterone suppression ≤50 ng/dL at day 29 and the cumulative probability of testosterone ≤50 ng/dL from day 29 to 85. Non-inferiority was prespecified at a margin of -10%. Secondary endpoints included significant castration (≤20 ng/dL), testosterone surge within 72 h following repeated dosing, and changes in luteinizing hormone, follicle-stimulating hormone, and prostate specific antigen levels.
RESULTS:
On day 29, in the LY01005 and goserelin implant groups, testosterone concentrations fell below medical-castration levels in 99.3% (142/143) and 100% (140/140) of patients, respectively, with a difference of -0.7% (95% confidence interval [CI], -3.9% to 2.0%) between the two groups. The cumulative probabilities of maintaining castration from days 29 to 85 were 99.3% and 97.8%, respectively, with a between-group difference of 1.5% (95% CI, -1.3% to 4.4%). Both results met the criterion for non-inferiority. Secondary endpoints were similar between groups. Both treatments were well-tolerated. LY01005 was associated with fewer injection-site reactions than the goserelin implant (0% vs . 1.4% [2/145]).
CONCLUSION:
LY01005 is as effective as goserelin implants in reducing testosterone to castration levels, with a similar safety profile.
TRIAL REGISTRATION
ClinicalTrials.gov, NCT04563936.
Humans
;
Male
;
Antineoplastic Agents, Hormonal/therapeutic use*
;
East Asian People
;
Gonadotropin-Releasing Hormone/agonists*
;
Goserelin/therapeutic use*
;
Prostate-Specific Antigen
;
Prostatic Neoplasms/drug therapy*
;
Testosterone
10.Concordance between three integrated scores based on prostate biopsy and grade-grouping of radical prostatectomy specimen.
Yao FU ; Jie CAI ; Yu CHEN ; Qiang ZHOU ; Yue Mei XU ; Jiong SHI ; Xiang Shan FAN
Chinese Journal of Pathology 2023;52(4):353-357
Objective: To analyze three different integrated scoring schemes of prostate biopsy and to compare their concordance with the scoring of radical prostatectomy specimens. Methods: A retrospective analysis of 556 patients with radical prostatectomy performed in Nanjing Drum Tower Hospital, Nanjing, China from 2017 to 2020. In these cases, whole organ sections were performed, the pathological data based on biopsy and radical prostatectomy specimens were summarized, and 3 integrated scores of prostate biopsy were calculated, namely the global score, the highest score and score of the largest volume. Results: Among the 556 patients, 104 cases (18.7%) were classified as WHO/ISUP grade group 1, 227 cases (40.8%) as grade group 2 (3+4=7); 143 cases (25.7%) as grade group 3 (4+3=7); 44 cases (7.9%) as grade group 4 (4+4=8) and 38 cases (6.8%) as grade group 5. Among the three comprehensive scoring methods for prostate cancer biopsy, the consistency of global score was the highest (62.4%). In the correlation analysis, the correlation between the scores of radical specimens and the global scores was highest (R=0.730, P<0.01), while the correlations of the scores based on radical specimens with highest scores and scores of the largest volume based on biopsy were insignificant (R=0.719, P<0.01; R=0.631, P<0.01, respectively). Univariate and multivariate analyses showed tPSA group and the three integrated scores of prostate biopsy were statistically correlated with extraglandular invasion, lymph node metastasis, perineural invasion and biochemical recurrence. Elevated global score was an independent prognostic risk factor for extraglandular invasion and biochemical recurrence in patients; increased serum tPSA was an independent prognostic risk factor for extraglandular invasion; increased hjighest score was an independent risk factor for perineural invasion. Conclusions: In this study, among the three different integrated scores, the overall score is most likely corresponded to the radical specimen grade group, but there is difference in various subgroup analyses. Integrated score of prostate biopsy can reflect grade group of radical prostatectomy specimens, thereby providing more clinical information for assisting in optimal patient management and consultation.
Male
;
Humans
;
Prostate/pathology*
;
Retrospective Studies
;
Prostatectomy/methods*
;
Biopsy
;
Prostatic Neoplasms/pathology*

Result Analysis
Print
Save
E-mail